Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol

Lindsey J. Wanberg; Kathleen M. Fletcher; Noah Goldfarb; Afsaneh Alavi

doi:10.1002/jvc2.346

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol

Lindsey J. Wanberg, Kathleen M. Fletcher, Noah Goldfarb, Afsaneh Alavi

Medicine - General Internal Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

We report a case of a 41-year-old woman who developed pregnancy-associated pyoderma gangrenosum (PG) at 4 weeks gestation. She was initially treated with prednisone, however, due to lack of improvement and risk of systemic corticosteroids in pregnancy, underwent a prednisone taper and was initiated on certolizumab pegol (CZP). The patient experienced complete wound re-epithelialization 1 month after CZP initiation. She had no pregnancy complications except for prednisone-associated gestational diabetes and gave birth to a healthy baby. CZP is a tumour necrosis factor-inhibitor with negligible placental transfer and no known adverse effects in pregnancy. Its efficacy and safety for autoinflammatory dermatoses in pregnancy are very promising. This is the first case to report CZP treatment for PG in a pregnant patient.

Original language	English (US)
Pages (from-to)	696-698
Number of pages	3
Journal	JEADV Clinical Practice
Volume	3
Issue number	2
DOIs	https://doi.org/10.1002/jvc2.346
State	Published - Jun 2024

Bibliographical note

Publisher Copyright:
© 2023 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Keywords

biologics
certolizumab pegol
neutrophilic dermatosis
pregnancy
pyoderma gangrenosum

Publisher link

10.1002/jvc2.346

Find It

Find It at U of M Libraries

Cite this

@article{8cbdf3d1bdf84c31a2e9b49033cd38d7,

title = "Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol",

abstract = "We report a case of a 41-year-old woman who developed pregnancy-associated pyoderma gangrenosum (PG) at 4 weeks gestation. She was initially treated with prednisone, however, due to lack of improvement and risk of systemic corticosteroids in pregnancy, underwent a prednisone taper and was initiated on certolizumab pegol (CZP). The patient experienced complete wound re-epithelialization 1 month after CZP initiation. She had no pregnancy complications except for prednisone-associated gestational diabetes and gave birth to a healthy baby. CZP is a tumour necrosis factor-inhibitor with negligible placental transfer and no known adverse effects in pregnancy. Its efficacy and safety for autoinflammatory dermatoses in pregnancy are very promising. This is the first case to report CZP treatment for PG in a pregnant patient.",

keywords = "biologics, certolizumab pegol, neutrophilic dermatosis, pregnancy, pyoderma gangrenosum",

author = "Wanberg, {Lindsey J.} and Fletcher, {Kathleen M.} and Noah Goldfarb and Afsaneh Alavi",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.",

year = "2024",

month = jun,

doi = "10.1002/jvc2.346",

language = "English (US)",

volume = "3",

pages = "696--698",

journal = "JEADV Clinical Practice",

issn = "2768-6566",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol

AU - Wanberg, Lindsey J.

AU - Fletcher, Kathleen M.

AU - Goldfarb, Noah

AU - Alavi, Afsaneh

PY - 2024/6

Y1 - 2024/6

N2 - We report a case of a 41-year-old woman who developed pregnancy-associated pyoderma gangrenosum (PG) at 4 weeks gestation. She was initially treated with prednisone, however, due to lack of improvement and risk of systemic corticosteroids in pregnancy, underwent a prednisone taper and was initiated on certolizumab pegol (CZP). The patient experienced complete wound re-epithelialization 1 month after CZP initiation. She had no pregnancy complications except for prednisone-associated gestational diabetes and gave birth to a healthy baby. CZP is a tumour necrosis factor-inhibitor with negligible placental transfer and no known adverse effects in pregnancy. Its efficacy and safety for autoinflammatory dermatoses in pregnancy are very promising. This is the first case to report CZP treatment for PG in a pregnant patient.

AB - We report a case of a 41-year-old woman who developed pregnancy-associated pyoderma gangrenosum (PG) at 4 weeks gestation. She was initially treated with prednisone, however, due to lack of improvement and risk of systemic corticosteroids in pregnancy, underwent a prednisone taper and was initiated on certolizumab pegol (CZP). The patient experienced complete wound re-epithelialization 1 month after CZP initiation. She had no pregnancy complications except for prednisone-associated gestational diabetes and gave birth to a healthy baby. CZP is a tumour necrosis factor-inhibitor with negligible placental transfer and no known adverse effects in pregnancy. Its efficacy and safety for autoinflammatory dermatoses in pregnancy are very promising. This is the first case to report CZP treatment for PG in a pregnant patient.

KW - biologics

KW - certolizumab pegol

KW - neutrophilic dermatosis

KW - pregnancy

KW - pyoderma gangrenosum

UR - http://www.scopus.com/inward/record.url?scp=85195051865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85195051865&partnerID=8YFLogxK

U2 - 10.1002/jvc2.346

DO - 10.1002/jvc2.346

M3 - Article

AN - SCOPUS:85195051865

SN - 2768-6566

VL - 3

SP - 696

EP - 698

JO - JEADV Clinical Practice

JF - JEADV Clinical Practice

IS - 2

ER -

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this